MERLIN-TIMI 36 evaluated a novel anti-ischemic agent, ranolazine, in patients with acute coronary syndromes. MAIN RESULTS: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA. 2007 Apr 25;297(16):1775-83. PRESENTATIONS TIMI 36 Slides Plasma Omega-6 Fatty Acids & the Risk of CV Events in Patients … Continue reading MERLIN-TIMI 36